CUBE vs IMDX · P/E 25, rev $1.07B vs rev $1.9M
CubeSmart (CUBE) versus Insight Molecular Diagnostics Inc. (IMDX) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Insight Molecular Diagnostics Inc. (IMDX) is a diagnostics & research company listed on US.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported IMDX revenue for 2024-12-31 was $1.9M. Net income was -$60.7M. Revenue was up 25.1% from 2023-12-31 to 2024-12-31. IMDX currently screens at market cap $0.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. IMDX currently screens at market cap $0.
Not investment advice. Open the CUBE and IMDX stock pages for the full models.
Not investment advice.